 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- | Journal: Learnings about A? from human brain recommend the use of a live-neuron bioassay for the discovery of next generation Alzheimer's disease immunotherapeutics. (Pubmed Central) - Mar 15, 2023
To test this principle, we directly compared 5 clinical antibodies (aducanumab, bapineuzumab,
- | SAR228810 / Sanofi
Journal: SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). (Pubmed Central) - Sep 1, 2019
To test this principle, we directly compared 5 clinical antibodies (aducanumab, bapineuzumab, Based on the improved efficacy/safety profile in non-clinical models of SAR228810, a first-in-man single and multiple dose administration clinical study has been initiated in AD patients.
- | SAR228810 / Sanofi
Trial completion: Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients (clinicaltrials.gov) - Mar 25, 2015
P1, N=48, Completed, Sponsor: Sanofi
Based on the improved efficacy/safety profile in non-clinical models of SAR228810, a first-in-man single and multiple dose administration clinical study has been initiated in AD patients. Active, not recruiting --> Completed
- SAR228810 / Sanofi
Enrollment closed: Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients (clinicaltrials.gov) - Apr 27, 2014
P1, N=48, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | SAR228810 / Sanofi
New P1 trial: Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients (clinicaltrials.gov) - Dec 1, 2011
P1, N=48, Active, not recruiting, Sponsor: Sanofi